Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Chronic Pancreatitis II: Pathophysiology

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

Chronic Pancreatitis I: Introduction

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction-Associated Steatotic Liver Disease.

The Kaohsiung journal of medical sciences·2026

Same author

Prevalence and associated factors of metabolic dysfunction-associated steatotic liver disease in Taiwan, 2001-2021.

Hepatology international·2026

Same author

Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis.

The American journal of gastroenterology·2026

Same author

Ambient nitrogen oxides exposure associated with hepatic steatosis in patients with chronic hepatitis B.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026

Same author

Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver-Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy.

The Kaohsiung journal of medical sciences·2026

Same author

Predicting non-alcoholic fatty liver disease (NAFLD) using machine learning algorithms: Evidence from a large-scale community cohort in Taiwan.

Bioscience trends·2026

Search research articles

Related Experiment Video

Updated: May 26, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Chronic hepatitis C infection in the elderly.

Chung-Feng Huang¹, Wan-Long Chuang, Ming-Lung Yu

¹Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.

The Kaohsiung Journal of Medical Sciences

|January 3, 2012

Summary

Treating elderly patients with chronic hepatitis C virus (HCV) is debated. Rapid virological response predicts success, and shorter treatment may improve outcomes and adherence in older adults.

More Related Videos

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

Related Experiment Videos

Last Updated: May 26, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

Area of Science:

Hepatology
Geriatric Medicine
Infectious Diseases

Background:

Chronic hepatitis C virus (HCV) prevalence increases with age.
Aging negatively impacts liver disease progression and treatment outcomes in HCV patients.
Efficacy and safety of HCV treatment in the elderly are debated due to study variations.

Purpose of the Study:

To evaluate the efficacy and safety of HCV treatment in elderly patients.
To identify predictive factors for successful treatment outcomes in older adults.
To explore the long-term benefits of interferon-based therapy in elderly HCV patients.

Main Methods:

Review of studies on HCV treatment in elderly populations.
Analysis of treatment regimens, including interferon-based therapies.
Assessment of factors predicting treatment success, such as rapid virological response.

Main Results:

Rapid virological response is a key predictor of successful HCV treatment in the elderly.
Shortened treatment durations may enhance adherence and reduce side effects in older patients.
Tailored regimens for super-responders could inform future elderly treatment strategies.

Conclusions:

HCV treatment in the elderly requires careful consideration of age-related factors.
Optimizing treatment duration and response monitoring can improve outcomes.
Further research into tailored regimens is needed for effective elderly HCV management.